advanced search

NASAL

NASAL DRUG DELIVERY VIA THE ORAL ROUTE USING A PMDI
NASAL
Dr Laurent Vecellio
NASAL DRUG DELIVERY VIA THE ORAL ROUTE USING A PMDI
Laurent Vecellio, Déborah Le Pennec and Alain Regard, Technology Product Manage discuss a study Nemera has funded into the retronose concept, using a pMDI to deliver to the nasal cavity via the oral route during exhalation through the nose.
EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY
CONNECTIVITY
Nemera
EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY
Nemera introduces the e-Novelia® and e-Advancia® add-ons for ophthalmic and nasal devices.
DRUG REPURPOSING – BROADENING PATIENT ACCESSIBILITY VIA A CHANGE IN DRUG DELIVERY SYSTEM
NASAL
Badre Hammond
Aptar Pharma
DRUG REPURPOSING – BROADENING PATIENT ACCESSIBILITY VIA A CHANGE IN DRUG DELIVERY SYSTEM
Badre Hammond, Gerallt Williams and Herve Pacaud discuss the growing trend of drug repurposing.
INFLUENCE OF THE HUMAN FACTOR ON NASAL DRUG DELIVERY DEVICE EVALUATION
NASAL
Pascale Farjas
Nemera
INFLUENCE OF THE HUMAN FACTOR ON NASAL DRUG DELIVERY DEVICE EVALUATION
Pascale Farjas, Alain Regard and Guillaume Grevin, discuss what is required of a modern nasal spray pump and how introducing the human factor showed a significant impact on the variability of delivered volume.
ADDRESSING THE CHALLENGES IN NASAL DEVICE TESTING: EVALUATION OF PUMP PERFORMANCE
NASAL
Heli Chauhan
Proveris Scientific
ADDRESSING THE CHALLENGES IN NASAL DEVICE TESTING: EVALUATION OF PUMP PERFORMANCE
Heli Chauhan details the myriad challenges facing the OINDP market, with a particular emphasis on nasal spray devices, when it comes to testing products on a mass-production scale, such as a lack of adequate testing equipment and the need to capture accurate data consistently. She goes on to offer a solution in the form of Indizo®, Proveris’ automated nasal spray testing apparatus.
THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY
NASAL
Pascale Farjas
Nemera
THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY
Pascale Farjas, Alain Regard, and Céline Petitcolas discuss the steps taken when designing a nasal spray device for the growing bioequivalence market and the key competencies, including experience with regulations and regulatory agencies in numerous geographic regions, that Nemera can offer throughout the process.
INNOVATIVE NASAL APPLICATION REQUIRES INNOVATIVE FILLING TECHNOLOGY
EXPERT VIEW
Dr Karlheinz Seyfang
INNOVATIVE NASAL APPLICATION REQUIRES INNOVATIVE FILLING TECHNOLOGY
Karlheinz Seyfang discusses the development of a system for the nasal delivery of a thixotropic gel formulation, from the design of the system through to the production line.
CONTROLLED-RELEASE SYSTEMS FOR PROTEINS & PEPTIDES
EXPERT VIEW
Dr S Mohan Mohanraj
CONTROLLED-RELEASE SYSTEMS FOR PROTEINS & PEPTIDES
S Mohan Mohanraj and Meier Kende discuss development of a viable intranasal microsphere-based delivery system and how it delivers a recombinant anthrax vaccine via two-dose immunisation.
A TRUE PLATFORM OFFERING EFFICIENT NASAL DOSE DELIVERY
NASAL
Pascale Farjas
Nemera
A TRUE PLATFORM OFFERING EFFICIENT NASAL DOSE DELIVERY
Millions of people suffering from allergic rhinitis use nasal sprays manufactured by Nemera every day. Pascale Farjas, provides an overview of an innovative nasal delivery system, Advancia®, a true platform.
BIOEQUIVALENCE FOR NASAL SPRAYS: IMPORTANCE OF DEVICE PERFORMANCE
NASAL
Pascale Farjas
Nemera
BIOEQUIVALENCE FOR NASAL SPRAYS: IMPORTANCE OF DEVICE PERFORMANCE
Pascale Farjas describes the company’s Device Equivalence Program, which enables Nemera to preselect and propose an appropriate delivery system per identified drug to companies wishing to save time in their nasal spray development pipeline.
SONIC NEBULISATION IN RHINOLOGY
NASAL
Dr Laurent Vecellio
SONIC NEBULISATION IN RHINOLOGY
Laurent Vecellio, Sandrine Le Guellec and Gilles Chantrel describe a sonic nasal nebuliser that operates with an acoustic frequency of 100Hz, and clinical studies demonstrating its efficacy in the delivery of treatments for CRS.
SCOPING THE DESIGN SPACE FOR GENERIC NASAL SPRAYS
NASAL
Dr Deborah Huck-Jones
Malvern Panalytical
SCOPING THE DESIGN SPACE FOR GENERIC NASAL SPRAYS
Deborah Huck-Jones and Paul Kippax discuss analytical methods that can be helpful for demonstrating bioequivalence in the development of generic nasal sprays.
Top